We propose here that VPS33B and VIPAS39 mutation screening in patients with normal GGT cholestasis could facilitate accurate diagnosis and the administration of supportive care at early stage, in addition to provide genetic counseling for the affected families. This evidence concerns the gene VPS33B and cholestasis.